Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27350276,PDI,"The rifabutin solid lipid nanoparticles (RFB-SLNs), prepared by the solvent diffusion evaporation method, had a size of 345 ± 17.96 nm and PDI of 0.321 ± 0.09.",Lipid Nanocarrier-Mediated Drug Delivery System to Enhance the Oral Bioavailability of Rifabutin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27350276/),,0.321,3897,DB00615,Rifabutin
,16203796,IC50,"The IC50 values of 17-AAG in A2780 and CH1 cells were 18.3 nmol/L (SD, 2.3) and 410.1 nmol/L (SD, 9.4), respectively.","Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203796/),[nM] / [l],18.3,11345,DB00615,Rifabutin
,16203796,IC50,"The IC50 values of 17-AAG in A2780 and CH1 cells were 18.3 nmol/L (SD, 2.3) and 410.1 nmol/L (SD, 9.4), respectively.","Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203796/),[nM] / [l],410.1,11346,DB00615,Rifabutin
,16203796,Peak concentrations,"Peak concentrations of 17-AAG achieved in A2780 and CH1 tumors were 15.6 and 16.5 micromol/L, respectively, and there was no significant difference between day 1 and 11 pharmacokinetic profiles.","Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203796/),[μM] / [l],15.6,11347,DB00615,Rifabutin
,16203796,Peak concentrations,"Peak concentrations of 17-AAG achieved in A2780 and CH1 tumors were 15.6 and 16.5 micromol/L, respectively, and there was no significant difference between day 1 and 11 pharmacokinetic profiles.","Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203796/),[μM] / [l],16.5,11348,DB00615,Rifabutin
,18591268,peak concentrations,"In cultured cells, both microparticles and dissolved drugs established peak concentrations of isoniazid ( approximately 1.4 and 1.1 microg/10(6) cells) and rifabutin ( approximately 2 microg/ml and approximately 1.4 microg/10(6) cells) within 10 min.","Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591268/),[μg] / [10(6)·cells],1.4,21084,DB00615,Rifabutin
,18591268,peak concentrations,"In cultured cells, both microparticles and dissolved drugs established peak concentrations of isoniazid ( approximately 1.4 and 1.1 microg/10(6) cells) and rifabutin ( approximately 2 microg/ml and approximately 1.4 microg/10(6) cells) within 10 min.","Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591268/),[μg] / [10(6)·cells],1.1,21085,DB00615,Rifabutin
,18591268,peak concentrations,"In cultured cells, both microparticles and dissolved drugs established peak concentrations of isoniazid ( approximately 1.4 and 1.1 microg/10(6) cells) and rifabutin ( approximately 2 microg/ml and approximately 1.4 microg/10(6) cells) within 10 min.","Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591268/),[μg] / [ml],2,21086,DB00615,Rifabutin
,18591268,serum half-life (t(1/2)),"The following pharmacokinetic parameters were calculated using WinNonlin from samples obtained after inhalation using an in-house apparatus (figures in parentheses refer to parameters obtained after intravenous administration of an equivalent amount, i.e., 100 microg of either drug, to parallel groups): isoniazid, serum half-life (t(1/2)) = 18.63 +/- 5.89 h (3.91 +/- 1.06 h), maximum concentration in serum (C(max)) = 2.37 +/- 0.23 microg x ml(-1) (3.24 +/- 0.57 microg x ml(-1)), area under the concentration-time curve from 0 to 24 h (AUC(0-24)) = 55.34 +/- 13.72 microg/ml(-1) h(-1) (16.64 +/- 1.80 microg/ml(-1) h(-1)), and clearance (CL) = 63.90 +/- 13.32 ml x h(-1) (4.43 +/- 1.85 ml x h(-1)); rifabutin, t(1/2) = 119.49 +/- 29.62 h (20.18 +/- 4.02 h), C(max) = 1.59 +/- 0.01 microg x ml(-1) (3.47 +/- 0.33 microg x ml(-1)), AUC(0-96) = 109.35 +/- 14.78 microg/ml(-1) h(-1) (90.82 +/- 7.46 microg/ml(-1) h(-1)), and CL = 11.68 +/- 7.00 ml x h(-1) (1.03 +/- 0.11 ml.h(-1)).","Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591268/),h,18.63,21087,DB00615,Rifabutin
,18591268,serum half-life (t(1/2)),"The following pharmacokinetic parameters were calculated using WinNonlin from samples obtained after inhalation using an in-house apparatus (figures in parentheses refer to parameters obtained after intravenous administration of an equivalent amount, i.e., 100 microg of either drug, to parallel groups): isoniazid, serum half-life (t(1/2)) = 18.63 +/- 5.89 h (3.91 +/- 1.06 h), maximum concentration in serum (C(max)) = 2.37 +/- 0.23 microg x ml(-1) (3.24 +/- 0.57 microg x ml(-1)), area under the concentration-time curve from 0 to 24 h (AUC(0-24)) = 55.34 +/- 13.72 microg/ml(-1) h(-1) (16.64 +/- 1.80 microg/ml(-1) h(-1)), and clearance (CL) = 63.90 +/- 13.32 ml x h(-1) (4.43 +/- 1.85 ml x h(-1)); rifabutin, t(1/2) = 119.49 +/- 29.62 h (20.18 +/- 4.02 h), C(max) = 1.59 +/- 0.01 microg x ml(-1) (3.47 +/- 0.33 microg x ml(-1)), AUC(0-96) = 109.35 +/- 14.78 microg/ml(-1) h(-1) (90.82 +/- 7.46 microg/ml(-1) h(-1)), and CL = 11.68 +/- 7.00 ml x h(-1) (1.03 +/- 0.11 ml.h(-1)).","Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591268/),h,3.91,21088,DB00615,Rifabutin
,18591268,maximum concentration in serum (C(max)),"The following pharmacokinetic parameters were calculated using WinNonlin from samples obtained after inhalation using an in-house apparatus (figures in parentheses refer to parameters obtained after intravenous administration of an equivalent amount, i.e., 100 microg of either drug, to parallel groups): isoniazid, serum half-life (t(1/2)) = 18.63 +/- 5.89 h (3.91 +/- 1.06 h), maximum concentration in serum (C(max)) = 2.37 +/- 0.23 microg x ml(-1) (3.24 +/- 0.57 microg x ml(-1)), area under the concentration-time curve from 0 to 24 h (AUC(0-24)) = 55.34 +/- 13.72 microg/ml(-1) h(-1) (16.64 +/- 1.80 microg/ml(-1) h(-1)), and clearance (CL) = 63.90 +/- 13.32 ml x h(-1) (4.43 +/- 1.85 ml x h(-1)); rifabutin, t(1/2) = 119.49 +/- 29.62 h (20.18 +/- 4.02 h), C(max) = 1.59 +/- 0.01 microg x ml(-1) (3.47 +/- 0.33 microg x ml(-1)), AUC(0-96) = 109.35 +/- 14.78 microg/ml(-1) h(-1) (90.82 +/- 7.46 microg/ml(-1) h(-1)), and CL = 11.68 +/- 7.00 ml x h(-1) (1.03 +/- 0.11 ml.h(-1)).","Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591268/),[μg] / [ml],2.37,21089,DB00615,Rifabutin
,18591268,maximum concentration in serum (C(max)),"The following pharmacokinetic parameters were calculated using WinNonlin from samples obtained after inhalation using an in-house apparatus (figures in parentheses refer to parameters obtained after intravenous administration of an equivalent amount, i.e., 100 microg of either drug, to parallel groups): isoniazid, serum half-life (t(1/2)) = 18.63 +/- 5.89 h (3.91 +/- 1.06 h), maximum concentration in serum (C(max)) = 2.37 +/- 0.23 microg x ml(-1) (3.24 +/- 0.57 microg x ml(-1)), area under the concentration-time curve from 0 to 24 h (AUC(0-24)) = 55.34 +/- 13.72 microg/ml(-1) h(-1) (16.64 +/- 1.80 microg/ml(-1) h(-1)), and clearance (CL) = 63.90 +/- 13.32 ml x h(-1) (4.43 +/- 1.85 ml x h(-1)); rifabutin, t(1/2) = 119.49 +/- 29.62 h (20.18 +/- 4.02 h), C(max) = 1.59 +/- 0.01 microg x ml(-1) (3.47 +/- 0.33 microg x ml(-1)), AUC(0-96) = 109.35 +/- 14.78 microg/ml(-1) h(-1) (90.82 +/- 7.46 microg/ml(-1) h(-1)), and CL = 11.68 +/- 7.00 ml x h(-1) (1.03 +/- 0.11 ml.h(-1)).","Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591268/),[μg] / [ml],3.24,21090,DB00615,Rifabutin
,18591268,area under the concentration-time curve from 0 to 24 h (AUC(0-24)),"The following pharmacokinetic parameters were calculated using WinNonlin from samples obtained after inhalation using an in-house apparatus (figures in parentheses refer to parameters obtained after intravenous administration of an equivalent amount, i.e., 100 microg of either drug, to parallel groups): isoniazid, serum half-life (t(1/2)) = 18.63 +/- 5.89 h (3.91 +/- 1.06 h), maximum concentration in serum (C(max)) = 2.37 +/- 0.23 microg x ml(-1) (3.24 +/- 0.57 microg x ml(-1)), area under the concentration-time curve from 0 to 24 h (AUC(0-24)) = 55.34 +/- 13.72 microg/ml(-1) h(-1) (16.64 +/- 1.80 microg/ml(-1) h(-1)), and clearance (CL) = 63.90 +/- 13.32 ml x h(-1) (4.43 +/- 1.85 ml x h(-1)); rifabutin, t(1/2) = 119.49 +/- 29.62 h (20.18 +/- 4.02 h), C(max) = 1.59 +/- 0.01 microg x ml(-1) (3.47 +/- 0.33 microg x ml(-1)), AUC(0-96) = 109.35 +/- 14.78 microg/ml(-1) h(-1) (90.82 +/- 7.46 microg/ml(-1) h(-1)), and CL = 11.68 +/- 7.00 ml x h(-1) (1.03 +/- 0.11 ml.h(-1)).","Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591268/),[μg] / [h·ml],55.34,21091,DB00615,Rifabutin
,18591268,area under the concentration-time curve from 0 to 24 h (AUC(0-24)),"The following pharmacokinetic parameters were calculated using WinNonlin from samples obtained after inhalation using an in-house apparatus (figures in parentheses refer to parameters obtained after intravenous administration of an equivalent amount, i.e., 100 microg of either drug, to parallel groups): isoniazid, serum half-life (t(1/2)) = 18.63 +/- 5.89 h (3.91 +/- 1.06 h), maximum concentration in serum (C(max)) = 2.37 +/- 0.23 microg x ml(-1) (3.24 +/- 0.57 microg x ml(-1)), area under the concentration-time curve from 0 to 24 h (AUC(0-24)) = 55.34 +/- 13.72 microg/ml(-1) h(-1) (16.64 +/- 1.80 microg/ml(-1) h(-1)), and clearance (CL) = 63.90 +/- 13.32 ml x h(-1) (4.43 +/- 1.85 ml x h(-1)); rifabutin, t(1/2) = 119.49 +/- 29.62 h (20.18 +/- 4.02 h), C(max) = 1.59 +/- 0.01 microg x ml(-1) (3.47 +/- 0.33 microg x ml(-1)), AUC(0-96) = 109.35 +/- 14.78 microg/ml(-1) h(-1) (90.82 +/- 7.46 microg/ml(-1) h(-1)), and CL = 11.68 +/- 7.00 ml x h(-1) (1.03 +/- 0.11 ml.h(-1)).","Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591268/),[μg] / [h·ml],16.64,21092,DB00615,Rifabutin
,18591268,clearance (CL),"The following pharmacokinetic parameters were calculated using WinNonlin from samples obtained after inhalation using an in-house apparatus (figures in parentheses refer to parameters obtained after intravenous administration of an equivalent amount, i.e., 100 microg of either drug, to parallel groups): isoniazid, serum half-life (t(1/2)) = 18.63 +/- 5.89 h (3.91 +/- 1.06 h), maximum concentration in serum (C(max)) = 2.37 +/- 0.23 microg x ml(-1) (3.24 +/- 0.57 microg x ml(-1)), area under the concentration-time curve from 0 to 24 h (AUC(0-24)) = 55.34 +/- 13.72 microg/ml(-1) h(-1) (16.64 +/- 1.80 microg/ml(-1) h(-1)), and clearance (CL) = 63.90 +/- 13.32 ml x h(-1) (4.43 +/- 1.85 ml x h(-1)); rifabutin, t(1/2) = 119.49 +/- 29.62 h (20.18 +/- 4.02 h), C(max) = 1.59 +/- 0.01 microg x ml(-1) (3.47 +/- 0.33 microg x ml(-1)), AUC(0-96) = 109.35 +/- 14.78 microg/ml(-1) h(-1) (90.82 +/- 7.46 microg/ml(-1) h(-1)), and CL = 11.68 +/- 7.00 ml x h(-1) (1.03 +/- 0.11 ml.h(-1)).","Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591268/),[ml] / [h],63.90,21093,DB00615,Rifabutin
,21682979,minimum inhibitory concentration [MIC],"Phenotypically, low-level rifampicin (RMP) resistance (minimum inhibitory concentration [MIC] 1-2 mg/l) was observed.",Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21682979/),[mg] / [l],1-2,21985,DB00615,Rifabutin
up to,21682979,MICs,"We retrospectively performed pharmacokinetic calculations to assess the potential for RMP treatment, from which we conclude that MICs for RMP up to 1 μg/ml may be safely overcome by applying 20 mg/kg RMP doses in treatment regimens.",Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21682979/),[μg] / [ml],1,21986,DB00615,Rifabutin
,7736687,oral bioavailability,Rifabutin has relatively low oral bioavailability; about 20% after single dose administration.,Clinical pharmacokinetics of rifabutin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736687/),%,20,23123,DB00615,Rifabutin
,7736687,elimination half-life,"The elimination half-life of rifabutin is long (45 hours) but, as a result of a very large volume of distribution (> 9 L/kg), average plasma concentrations remain relatively low after repeated administration of standard doses.",Clinical pharmacokinetics of rifabutin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736687/),h,45,23124,DB00615,Rifabutin
>,7736687,volume of distribution,"The elimination half-life of rifabutin is long (45 hours) but, as a result of a very large volume of distribution (> 9 L/kg), average plasma concentrations remain relatively low after repeated administration of standard doses.",Clinical pharmacokinetics of rifabutin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736687/),[l] / [kg],9,23125,DB00615,Rifabutin
,15718306,clearance,"At the MTD, the clearance and half-life (t(1/2)) of 17-AAG were 11.6 L/h/m(2) and 4.15 hours, respectively; whereas the active metabolite 17-aminogeldanamycin had a t(1/2) of 7.63 hours.",Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15718306/),[h·l] / [m(2],11.6,26864,DB00615,Rifabutin
,15718306,half-life (t(1/2)),"At the MTD, the clearance and half-life (t(1/2)) of 17-AAG were 11.6 L/h/m(2) and 4.15 hours, respectively; whereas the active metabolite 17-aminogeldanamycin had a t(1/2) of 7.63 hours.",Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15718306/),h,4.15,26865,DB00615,Rifabutin
,15718306,t(1/2),"At the MTD, the clearance and half-life (t(1/2)) of 17-AAG were 11.6 L/h/m(2) and 4.15 hours, respectively; whereas the active metabolite 17-aminogeldanamycin had a t(1/2) of 7.63 hours.",Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15718306/),h,7.63,26866,DB00615,Rifabutin
,15718306,MTD,The MTD of weekly 17-AAG is 308 mg/m(2).,Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15718306/),[mg] / [m(2],308,26867,DB00615,Rifabutin
,32816220,time to maximum plasma concentration,"Following oral administration, doravirine is rapidly absorbed (median time to maximum plasma concentration, 1-4 h) and undergoes cytochrome P450 (CYP)3A-mediated oxidative metabolism.",Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816220/),h,1-4,31275,DB00615,Rifabutin
,32816220,AUC0-24,"Steady-state geometric means for AUC0-24, C24, and Cmax in individuals with HIV-1 following administration of doravirine 100 mg once daily are 37.8 μM·h, 930 nM, and 2260 nM, respectively.",Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816220/),h·μM,37.8,31276,DB00615,Rifabutin
,32816220,C24,"Steady-state geometric means for AUC0-24, C24, and Cmax in individuals with HIV-1 following administration of doravirine 100 mg once daily are 37.8 μM·h, 930 nM, and 2260 nM, respectively.",Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816220/),nM,930,31277,DB00615,Rifabutin
,32816220,Cmax,"Steady-state geometric means for AUC0-24, C24, and Cmax in individuals with HIV-1 following administration of doravirine 100 mg once daily are 37.8 μM·h, 930 nM, and 2260 nM, respectively.",Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816220/),nM,2260,31278,DB00615,Rifabutin
,22397370,RFB/INH,The RFB/INH in the lungs (101.10 ± 12.90/101.07 ± 8.09 μg/g of tissue) was twice that of the liver concentrations (60.22 ± 04.97/52.08 ± 4.62 μg/g) and four times that of the kidneys (22.89 ± 05.22/30.25 ± 3.71 μg/g).,Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),[μg] / [g],101.10,32012,DB00615,Rifabutin
,22397370,RFB/INH,The RFB/INH in the lungs (101.10 ± 12.90/101.07 ± 8.09 μg/g of tissue) was twice that of the liver concentrations (60.22 ± 04.97/52.08 ± 4.62 μg/g) and four times that of the kidneys (22.89 ± 05.22/30.25 ± 3.71 μg/g).,Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),[μg] / [g],101.07,32013,DB00615,Rifabutin
,22397370,RFB/INH,The RFB/INH in the lungs (101.10 ± 12.90/101.07 ± 8.09 μg/g of tissue) was twice that of the liver concentrations (60.22 ± 04.97/52.08 ± 4.62 μg/g) and four times that of the kidneys (22.89 ± 05.22/30.25 ± 3.71 μg/g).,Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),[μg] / [g],60.22,32014,DB00615,Rifabutin
,22397370,RFB/INH,The RFB/INH in the lungs (101.10 ± 12.90/101.07 ± 8.09 μg/g of tissue) was twice that of the liver concentrations (60.22 ± 04.97/52.08 ± 4.62 μg/g) and four times that of the kidneys (22.89 ± 05.22/30.25 ± 3.71 μg/g).,Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),[μg] / [g],52.08,32015,DB00615,Rifabutin
,22397370,RFB/INH,The RFB/INH in the lungs (101.10 ± 12.90/101.07 ± 8.09 μg/g of tissue) was twice that of the liver concentrations (60.22 ± 04.97/52.08 ± 4.62 μg/g) and four times that of the kidneys (22.89 ± 05.22/30.25 ± 3.71 μg/g).,Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),[μg] / [g],22.89,32016,DB00615,Rifabutin
,22397370,RFB/INH,The RFB/INH in the lungs (101.10 ± 12.90/101.07 ± 8.09 μg/g of tissue) was twice that of the liver concentrations (60.22 ± 04.97/52.08 ± 4.62 μg/g) and four times that of the kidneys (22.89 ± 05.22/30.25 ± 3.71 μg/g).,Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),[μg] / [g],30.25,32017,DB00615,Rifabutin
,22397370,elimination half-life (t(1/2)),"Thus, the elimination half-life (t(1/2)) of RFB and INH was calculated as 8.01 ± 0.5 and 2.49 ± 0.23 h, respectively, upon intravenous (iv) administration, and as 13.8 ± 0.8 and 10.43 ± 0.77 h following a single inhalation; or 13.36 ± 3.51 and 10.13 ± 3.01 at a presumed steady state (day 60 of dosing).",Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),h,8.01,32018,DB00615,Rifabutin
,22397370,elimination half-life (t(1/2)),"Thus, the elimination half-life (t(1/2)) of RFB and INH was calculated as 8.01 ± 0.5 and 2.49 ± 0.23 h, respectively, upon intravenous (iv) administration, and as 13.8 ± 0.8 and 10.43 ± 0.77 h following a single inhalation; or 13.36 ± 3.51 and 10.13 ± 3.01 at a presumed steady state (day 60 of dosing).",Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),h,2.49,32019,DB00615,Rifabutin
,22397370,elimination half-life (t(1/2)),"Thus, the elimination half-life (t(1/2)) of RFB and INH was calculated as 8.01 ± 0.5 and 2.49 ± 0.23 h, respectively, upon intravenous (iv) administration, and as 13.8 ± 0.8 and 10.43 ± 0.77 h following a single inhalation; or 13.36 ± 3.51 and 10.13 ± 3.01 at a presumed steady state (day 60 of dosing).",Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),h,13.8,32020,DB00615,Rifabutin
,22397370,elimination half-life (t(1/2)),"Thus, the elimination half-life (t(1/2)) of RFB and INH was calculated as 8.01 ± 0.5 and 2.49 ± 0.23 h, respectively, upon intravenous (iv) administration, and as 13.8 ± 0.8 and 10.43 ± 0.77 h following a single inhalation; or 13.36 ± 3.51 and 10.13 ± 3.01 at a presumed steady state (day 60 of dosing).",Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),h,10.43,32021,DB00615,Rifabutin
,22397370,elimination half-life (t(1/2)),"Thus, the elimination half-life (t(1/2)) of RFB and INH was calculated as 8.01 ± 0.5 and 2.49 ± 0.23 h, respectively, upon intravenous (iv) administration, and as 13.8 ± 0.8 and 10.43 ± 0.77 h following a single inhalation; or 13.36 ± 3.51 and 10.13 ± 3.01 at a presumed steady state (day 60 of dosing).",Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),,13.36,32022,DB00615,Rifabutin
,22397370,elimination half-life (t(1/2)),"Thus, the elimination half-life (t(1/2)) of RFB and INH was calculated as 8.01 ± 0.5 and 2.49 ± 0.23 h, respectively, upon intravenous (iv) administration, and as 13.8 ± 0.8 and 10.43 ± 0.77 h following a single inhalation; or 13.36 ± 3.51 and 10.13 ± 3.01 at a presumed steady state (day 60 of dosing).",Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397370/),,10.13,32023,DB00615,Rifabutin
,15774780,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) of 17-AAG at 40 and 56 mg/m(2) were 1,724 and 2,046 ng/mL, respectively; the average plasma exposures (AUC) were 2,809 and 6,708 hours.",Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15774780/),[ng] / [ml],"1,724",37487,DB00615,Rifabutin
,15774780,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) of 17-AAG at 40 and 56 mg/m(2) were 1,724 and 2,046 ng/mL, respectively; the average plasma exposures (AUC) were 2,809 and 6,708 hours.",Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15774780/),[ng] / [ml],"2,046",37488,DB00615,Rifabutin
,15774780,plasma exposures (AUC),"The maximum plasma concentrations (C(max)) of 17-AAG at 40 and 56 mg/m(2) were 1,724 and 2,046 ng/mL, respectively; the average plasma exposures (AUC) were 2,809 and 6,708 hours.",Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15774780/),h,"2,809",37489,DB00615,Rifabutin
,15774780,plasma exposures (AUC),"The maximum plasma concentrations (C(max)) of 17-AAG at 40 and 56 mg/m(2) were 1,724 and 2,046 ng/mL, respectively; the average plasma exposures (AUC) were 2,809 and 6,708 hours.",Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15774780/),h,"6,708",37490,DB00615,Rifabutin
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],140,40634,DB00615,Rifabutin
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],100,40635,DB00615,Rifabutin
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],136,40636,DB00615,Rifabutin
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],128,40637,DB00615,Rifabutin
,14571691,intrinsic clearances,The intrinsic clearances of 17AAG and 17AG in the liver were uniquely identified using local models and were estimated to be 4.93 ml/hr and 3.34 ml/hr.,Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571691/),[ml] / [h],4.93,41044,DB00615,Rifabutin
,14571691,intrinsic clearances,The intrinsic clearances of 17AAG and 17AG in the liver were uniquely identified using local models and were estimated to be 4.93 ml/hr and 3.34 ml/hr.,Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571691/),[ml] / [h],3.34,41045,DB00615,Rifabutin
,14571691,vascular-interstitial permeability surface-area product,Estimates of the vascular-interstitial permeability surface-area product were similar for 17AAG and 17AG (0.23 ml/hr and 0.26 ml/hr).,Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571691/),[ml] / [h],0.23,41046,DB00615,Rifabutin
,14571691,vascular-interstitial permeability surface-area product,Estimates of the vascular-interstitial permeability surface-area product were similar for 17AAG and 17AG (0.23 ml/hr and 0.26 ml/hr).,Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571691/),[ml] / [h],0.26,41047,DB00615,Rifabutin
,14571691,half-life of endogenous protein turnover,"The half-life of endogenous protein turnover was estimated to be 22.6 hr for Raf-1 and 8.6 hr for p185erbB2, and both were comparable to corresponding values measured in vitro.",Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571691/),h,22.6,41048,DB00615,Rifabutin
,14571691,half-life of endogenous protein turnover,"The half-life of endogenous protein turnover was estimated to be 22.6 hr for Raf-1 and 8.6 hr for p185erbB2, and both were comparable to corresponding values measured in vitro.",Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571691/),h,8.6,41049,DB00615,Rifabutin
,15844071,area under the concentration-time curve (AUC(0-24)),"The median rifabutin area under the concentration-time curve (AUC(0-24)) was lower for patients with than for patients without ARR failure or relapse (3.3 vs. 5.2 microg*h/mL; P = .06, by the Mann-Whitney exact test).",Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844071/),[h·μg] / [ml],3.3,42892,DB00615,Rifabutin
,15844071,area under the concentration-time curve (AUC(0-24)),"The median rifabutin area under the concentration-time curve (AUC(0-24)) was lower for patients with than for patients without ARR failure or relapse (3.3 vs. 5.2 microg*h/mL; P = .06, by the Mann-Whitney exact test).",Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844071/),[h·μg] / [ml],5.2,42893,DB00615,Rifabutin
,15844071,AUC(0-24),"In a multivariate analysis adjusted for CD4+ T cell count, the mean rifabutin AUC(0-24) was significantly lower for patients with ARR failure or relapse than for other patients (3.0 microg*h/mL [95% confidence interval {CI}, 1.9-4.5] vs. 5.2 microg*h/mL [95% CI, 4.6-5.8]; P = .02, by analysis of covariance).",Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844071/),[h·μg] / [ml],3.0,42894,DB00615,Rifabutin
,15844071,AUC(0-24),"In a multivariate analysis adjusted for CD4+ T cell count, the mean rifabutin AUC(0-24) was significantly lower for patients with ARR failure or relapse than for other patients (3.0 microg*h/mL [95% confidence interval {CI}, 1.9-4.5] vs. 5.2 microg*h/mL [95% CI, 4.6-5.8]; P = .02, by analysis of covariance).",Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844071/),[h·μg] / [ml],5.2,42895,DB00615,Rifabutin
,15844071,AUC(0-12),"The median isoniazid AUC(0-12) was not significantly associated with ARR failure or relapse (20.6 vs. 28.0 microg*h/mL; P = .24, by the Mann-Whitney exact test).",Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844071/),[h·μg] / [ml],20.6,42896,DB00615,Rifabutin
,15844071,AUC(0-12),"The median isoniazid AUC(0-12) was not significantly associated with ARR failure or relapse (20.6 vs. 28.0 microg*h/mL; P = .24, by the Mann-Whitney exact test).",Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844071/),[h·μg] / [ml],28.0,42897,DB00615,Rifabutin
,8983397,elimination rate constant (k10),Parameter estimates showed an elimination rate constant (k10) of about 0.12-0.14 h-1 which was independent of the single or multiple-dosing condition.,A model based assessment of redistribution dependent elimination and bioavailability of rifabutin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983397/),1/[h],0.12-0.14,54096,DB00615,Rifabutin
,8983397,k21,"The mean rate of drug redistribution from the tissue compartment (k21; 0.04-0.06 h-1) was twofold to threefold lower than k10, and, with a large steady-state distribution volume (Vss/F after a single dose, 1630 L), RIF elimination appears to be dependent on drug redistribution.",A model based assessment of redistribution dependent elimination and bioavailability of rifabutin. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983397/),1/[h],0.04-0.06,54097,DB00615,Rifabutin
,8983397,steady-state distribution volume (Vss/F,"The mean rate of drug redistribution from the tissue compartment (k21; 0.04-0.06 h-1) was twofold to threefold lower than k10, and, with a large steady-state distribution volume (Vss/F after a single dose, 1630 L), RIF elimination appears to be dependent on drug redistribution.",A model based assessment of redistribution dependent elimination and bioavailability of rifabutin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983397/),l,1630,54098,DB00615,Rifabutin
,29718967,maximal effect,"Single oral doses of bedaquiline produced readily detectable WBA ex vivo, reaching a maximal effect of -0.28 log/day, with negative values indicating bacterial killing.",Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29718967/),[log] / [d],-,58488,DB00615,Rifabutin
,29718967,maximal effect,"Single oral doses of bedaquiline produced readily detectable WBA ex vivo, reaching a maximal effect of -0.28 log/day, with negative values indicating bacterial killing.",Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29718967/),[log] / [d],0.28,58489,DB00615,Rifabutin
,29718967,Plasma concentrations,Plasma concentrations of 355 ng/ml were sufficient for intracellular mycobacteriostasis.,Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29718967/),[ng] / [ml],355,58490,DB00615,Rifabutin
,29718967,maximal effects,"Combined dosing with rifampin or rifabutin produced maximal effects of -0.91 and -0.79 log/d, respectively.",Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29718967/),[log] / [d],0.91,58491,DB00615,Rifabutin
,29718967,maximal effects,"Combined dosing with rifampin or rifabutin produced maximal effects of -0.91 and -0.79 log/d, respectively.",Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29718967/),[log] / [d],0.79,58492,DB00615,Rifabutin
,15503027,Volumes of distribution,Volumes of distribution were 24.2 and 89.6 l for 17AAG.,Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15503027/),l,24.2,67730,DB00615,Rifabutin
,15503027,Volumes of distribution,Volumes of distribution were 24.2 and 89.6 l for 17AAG.,Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15503027/),l,89.6,67731,DB00615,Rifabutin
,15503027,Total elimination clearances,"Total elimination clearances were 26.7 and 21.3 l/h for 17AAG and 17AG, respectively.",Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15503027/),[l] / [h],26.7,67732,DB00615,Rifabutin
,15503027,Total elimination clearances,"Total elimination clearances were 26.7 and 21.3 l/h for 17AAG and 17AG, respectively.",Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15503027/),[l] / [h],21.3,67733,DB00615,Rifabutin
,15867239,maximum tolerated dose,The maximum tolerated dose was 295 mg/m2.,"Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15867239/),[mg] / [m2],295,74380,DB00615,Rifabutin
,34398956,AUC12,"Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL.",Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34398956/),[h·ng] / [ml],157 203,74788,DB00615,Rifabutin
,34398956,Ctrough,"Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL.",Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34398956/),[ng] / [ml],9876,74789,DB00615,Rifabutin
,34398956,AUC24,"Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL.",Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34398956/),[h·ng] / [ml],7374,74790,DB00615,Rifabutin
,34398956,Ctrough,"Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL.",Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34398956/),[ng] / [ml],208,74791,DB00615,Rifabutin
<,34398956,Cmax,"Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL.",Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34398956/),[ng] / [ml],250,74792,DB00615,Rifabutin
,22678727,AUC(0-12),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[h·μg] / [ml],187.5,77156,DB00615,Rifabutin
,22678727,AUC(0-12),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[h·μg] / [ml],161.8,77157,DB00615,Rifabutin
,22678727,AUC(0-12),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[h·μg] / [ml],121.1,77158,DB00615,Rifabutin
,22678727,C(trough),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[μg] / [ml],13.2,77159,DB00615,Rifabutin
,22678727,C(trough),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[μg] / [ml],10.0,77160,DB00615,Rifabutin
,22678727,C(trough),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[μg] / [ml],7.7,77161,DB00615,Rifabutin
,22678727,C(max),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[μg] / [ml],18.7,77162,DB00615,Rifabutin
,22678727,C(max),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[μg] / [ml],15.9,77163,DB00615,Rifabutin
,22678727,C(max),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[μg] / [ml],13.3,77164,DB00615,Rifabutin
,22678727,apparent oral clearance (CL/F),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[l] / [h·kg],0.035,77165,DB00615,Rifabutin
,22678727,apparent oral clearance (CL/F),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[l] / [h·kg],0.037,77166,DB00615,Rifabutin
,22678727,apparent oral clearance (CL/F),"In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg.",Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678727/),[l] / [h·kg],0.045,77167,DB00615,Rifabutin
,11452241,V/F,"Final parameter estimates were 1.40 L/kg for V/F, 0.0283 L/kg/h for CL/F, and 2.66 for the absorption rate constant.",Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452241/),[l] / [kg],1.40,77504,DB00615,Rifabutin
,11452241,CL/F,"Final parameter estimates were 1.40 L/kg for V/F, 0.0283 L/kg/h for CL/F, and 2.66 for the absorption rate constant.",Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452241/),[l] / [h·kg],0.0283,77505,DB00615,Rifabutin
,11452241,absorption rate constant,"Final parameter estimates were 1.40 L/kg for V/F, 0.0283 L/kg/h for CL/F, and 2.66 for the absorption rate constant.",Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452241/),,2.66,77506,DB00615,Rifabutin
,30797270,peak concentration (Cmax),The peak concentration (Cmax) of both doses were within the therapeutic range (0.45-0.90 μg/ml) of RBT.,Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30797270/),[μg] / [ml],0.45-0.90,79896,DB00615,Rifabutin
,27095353,Aerodynamic diameters,Aerodynamic diameters of formulations were 0.7-4.7 μm.,Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095353/),μm,0.7-4.7,85049,DB00615,Rifabutin
,27095353,AUC0-48,"Inhaled particles reached deep lungs and were phagocytosed by alveolar macrophages, yielding AUC0-48 of 102 compared to 0.1 μg/ml × h obtained with equivalent intravenous dose.",Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095353/),[μg] / [h·ml],102,85050,DB00615,Rifabutin
,27095353,AUC0-48,"Inhaled particles reached deep lungs and were phagocytosed by alveolar macrophages, yielding AUC0-48 of 102 compared to 0.1 μg/ml × h obtained with equivalent intravenous dose.",Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095353/),[μg] / [h·ml],0.1,85051,DB00615,Rifabutin
,8645788,terminal half-life,"Except for a statistically significant decrease (28%) in the terminal half-life of zidovudine from 1.5 to 1.1 hours (P = .005) after coadministration of both agents for 14 days, concurrent administration of rifabutin for 7 or 14 days had no statistically significant effects on zidovudine plasma and urine pharmacokinetic parameters (the difference among treatment means was < 25%).",Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645788/),h,1.5,97070,DB00615,Rifabutin
,8645788,terminal half-life,"Except for a statistically significant decrease (28%) in the terminal half-life of zidovudine from 1.5 to 1.1 hours (P = .005) after coadministration of both agents for 14 days, concurrent administration of rifabutin for 7 or 14 days had no statistically significant effects on zidovudine plasma and urine pharmacokinetic parameters (the difference among treatment means was < 25%).",Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645788/),h,1.1,97071,DB00615,Rifabutin
,8968354,systemic clearance,"After i.v. doses of 1,5, 10 and 25 mg/kg the systemic clearance was 0.7 to 1.0 liters/hr/kg; the volume of distribution was 4.4 liters/kg for the 1 mg/kg dose and 7.4 to 7.7 liters/kg for the 5 to 25 mg/kg doses, and the half-life ranged from 4.4 to 9.1 hr.",In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968354/),[l] / [h·kg],0.7 to 1.0,99690,DB00615,Rifabutin
,8968354,volume of distribution,"After i.v. doses of 1,5, 10 and 25 mg/kg the systemic clearance was 0.7 to 1.0 liters/hr/kg; the volume of distribution was 4.4 liters/kg for the 1 mg/kg dose and 7.4 to 7.7 liters/kg for the 5 to 25 mg/kg doses, and the half-life ranged from 4.4 to 9.1 hr.",In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968354/),[l] / [kg],4,99691,DB00615,Rifabutin
,8968354,volume of distribution,"After i.v. doses of 1,5, 10 and 25 mg/kg the systemic clearance was 0.7 to 1.0 liters/hr/kg; the volume of distribution was 4.4 liters/kg for the 1 mg/kg dose and 7.4 to 7.7 liters/kg for the 5 to 25 mg/kg doses, and the half-life ranged from 4.4 to 9.1 hr.",In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968354/),[l] / [kg],7.4 to 7.7,99692,DB00615,Rifabutin
,8968354,half-life,"After i.v. doses of 1,5, 10 and 25 mg/kg the systemic clearance was 0.7 to 1.0 liters/hr/kg; the volume of distribution was 4.4 liters/kg for the 1 mg/kg dose and 7.4 to 7.7 liters/kg for the 5 to 25 mg/kg doses, and the half-life ranged from 4.4 to 9.1 hr.",In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968354/),h,4.4 to 9.1,99693,DB00615,Rifabutin
>,8968354,Bioavailability,"Bioavailability after oral administration of 25 and 1 mg/kg rifabutin was > 90% and 44%, respectively, suggesting significant first-pass metabolism of the lower dose.",In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968354/),%,90,99694,DB00615,Rifabutin
,8968354,Bioavailability,"Bioavailability after oral administration of 25 and 1 mg/kg rifabutin was > 90% and 44%, respectively, suggesting significant first-pass metabolism of the lower dose.",In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968354/),%,44,99695,DB00615,Rifabutin
,8968354,rate of,"The rate of rifabutin metabolism by enterocyte microsomes was > 10 times higher than that by liver microsomes, i.e., 84 and 8 pmol/min/mg protein, respectively.",In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968354/),[pM] / [mg·min],84,99696,DB00615,Rifabutin
,8968354,rate of,"The rate of rifabutin metabolism by enterocyte microsomes was > 10 times higher than that by liver microsomes, i.e., 84 and 8 pmol/min/mg protein, respectively.",In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968354/),[pM] / [mg·min],8,99697,DB00615,Rifabutin
,8968354,metabolism,"The rate of rifabutin metabolism by enterocyte microsomes was > 10 times higher than that by liver microsomes, i.e., 84 and 8 pmol/min/mg protein, respectively.",In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968354/),[pM] / [mg·min],84,99698,DB00615,Rifabutin
,8968354,metabolism,"The rate of rifabutin metabolism by enterocyte microsomes was > 10 times higher than that by liver microsomes, i.e., 84 and 8 pmol/min/mg protein, respectively.",In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968354/),[pM] / [mg·min],8,99699,DB00615,Rifabutin
,10223941,maximum concentrations,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),[μg] / [ml],14.09,106924,DB00615,Rifabutin
,10223941,maximum concentrations,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),[μg] / [ml],373.63,106925,DB00615,Rifabutin
,10223941,maximum concentrations,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),μg,9.42,106926,DB00615,Rifabutin
,10223941,maximum concentrations,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),μg,256.10,106927,DB00615,Rifabutin
,10223941,areas under the curve from time zero to infinity,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),[μg] / [ml],373.63,106928,DB00615,Rifabutin
,10223941,areas under the curve from time zero to infinity,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),μg,256.10,106929,DB00615,Rifabutin
over,10406208,recovery,The recovery was over 71%.,Specific high-performance liquid chromatography assay for determination of rifabutin plasma concentration following Extrelut column extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10406208/),%,71,118473,DB00615,Rifabutin
,2552902,terminal half-life,The plasma concentration data were best described by a two-compartment open model with a terminal half-life of 36 h.,Pharmacokinetics of rifabutin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2552902/),h,36,134851,DB00615,Rifabutin
,2552902,Peak,"Peak and trough concentrations for the 1,200-mg dose were 907 and 194 ng/ml, respectively.",Pharmacokinetics of rifabutin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2552902/),[ng] / [ml],907,134852,DB00615,Rifabutin
,2552902,trough concentrations,"Peak and trough concentrations for the 1,200-mg dose were 907 and 194 ng/ml, respectively.",Pharmacokinetics of rifabutin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2552902/),[ng] / [ml],194,134853,DB00615,Rifabutin
,2552902,Total body clearance,Total body clearance was 10 to 18 liters/h.,Pharmacokinetics of rifabutin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2552902/),[l] / [h],10 to 18,134854,DB00615,Rifabutin
,2552902,Oral bioavailability,Oral bioavailability was 12 to 20%.,Pharmacokinetics of rifabutin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2552902/),%,12 to 20,134855,DB00615,Rifabutin
,2552902,free fraction,The drug was moderately bound to plasma proteins with a free fraction of 29 +/- 2% (mean +/- standard deviation).,Pharmacokinetics of rifabutin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2552902/),%,29,134856,DB00615,Rifabutin
,2552902,Renal clearance,Renal clearance was 1.5 +/- 0.2 liters/h.,Pharmacokinetics of rifabutin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2552902/),[l] / [h],1.5,134857,DB00615,Rifabutin
,2552902,volume of distribution,"The volume of distribution was large (8 to 9 liters/kg), suggesting extensive distribution into the tissues.",Pharmacokinetics of rifabutin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2552902/),[l] / [kg],8 to 9,134858,DB00615,Rifabutin
,31969147,Cmax,"The medians LPV Cmax and Tmax were respectively, 20 μg/mL and 4 h for the RBT 150 mg group (arm A) and 7.7 μg/mL and 3 h for the RBT 300 mg group (arm B).",Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969147/),[μg] / [ml],20,136587,DB00615,Rifabutin
,31969147,Cmax,"The medians LPV Cmax and Tmax were respectively, 20 μg/mL and 4 h for the RBT 150 mg group (arm A) and 7.7 μg/mL and 3 h for the RBT 300 mg group (arm B).",Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969147/),[μg] / [ml],7.7,136588,DB00615,Rifabutin
,31969147,Tmax,"The medians LPV Cmax and Tmax were respectively, 20 μg/mL and 4 h for the RBT 150 mg group (arm A) and 7.7 μg/mL and 3 h for the RBT 300 mg group (arm B).",Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969147/),h,4,136589,DB00615,Rifabutin
,31969147,Tmax,"The medians LPV Cmax and Tmax were respectively, 20 μg/mL and 4 h for the RBT 150 mg group (arm A) and 7.7 μg/mL and 3 h for the RBT 300 mg group (arm B).",Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969147/),h,3,136590,DB00615,Rifabutin
,31969147,AUC0-12,The AUC0-12 of LPV was 111.8 μg h/mL in patients belonging to arm A versus 69.9 μg/mL for those in arm B (p = 0.313).,Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969147/),[h·μg] / [ml],111.8,136591,DB00615,Rifabutin
,31969147,AUC0-12,The AUC0-12 of LPV was 111.8 μg h/mL in patients belonging to arm A versus 69.9 μg/mL for those in arm B (p = 0.313).,Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969147/),[μg] / [ml],69.9,136592,DB00615,Rifabutin
lower,31969147,C0,The C0 of LPV was lower than 4 μg/mL in three patients receiving RBT 300 mg.,Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969147/),[μg] / [ml],4,136593,DB00615,Rifabutin
,31969147,AUC0-12,The AUC0-12 of RTV in arm A was 12.7 μg h/mL versus 6.6 μg h/ml in arm B (p = 0.313).,Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969147/),[h·μg] / [ml],12.7,136594,DB00615,Rifabutin
,31969147,AUC0-12,The AUC0-12 of RTV in arm A was 12.7 μg h/mL versus 6.6 μg h/ml in arm B (p = 0.313).,Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969147/),[h·μg] / [ml],6.6,136595,DB00615,Rifabutin
,9210686,maximum concentration in plasma (Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[ng] / [ml],511,141082,DB00615,Rifabutin
,9210686,maximum concentration in plasma (Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[ng] / [ml],525,141083,DB00615,Rifabutin
,9210686,time at which,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),h,3.0,141084,DB00615,Rifabutin
,9210686,Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),h,3.0,141085,DB00615,Rifabutin
,9210686,Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),h,2.5,141086,DB00615,Rifabutin
,9210686,area under the concentration-time curve from 0 to 24 h (AUC(0-tau)),"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[h·ng] / [ml],"5,650",141087,DB00615,Rifabutin
,9210686,area under the concentration-time curve from 0 to 24 h (AUC(0-tau)),"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[h·ng] / [ml],"5,023",141088,DB00615,Rifabutin
,9210686,oral clearance,"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[l] / [h·kg],1.28,141089,DB00615,Rifabutin
,9210686,oral clearance,"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[l] / [h·kg],1.18,141090,DB00615,Rifabutin
,26321516,AUC0-last,"The AUC0-last values were (4.03 ± 0.60) and (5.44 ± 1.15) μg h mL(-1) upon 97/78 administration alone, while the values were decreased to (1.13 ± 0.10) and (1.23 ± 1.13) μg h mL(-1) upon rifabutin co-administration in male and female rats respectively.",Rifabutin reduces systemic exposure of an antimalarial drug 97/78 upon co-administration in rats: An in-vivo &in-vitro analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26321516/),[h·μg] / [ml],4.03,148341,DB00615,Rifabutin
,26321516,AUC0-last,"The AUC0-last values were (4.03 ± 0.60) and (5.44 ± 1.15) μg h mL(-1) upon 97/78 administration alone, while the values were decreased to (1.13 ± 0.10) and (1.23 ± 1.13) μg h mL(-1) upon rifabutin co-administration in male and female rats respectively.",Rifabutin reduces systemic exposure of an antimalarial drug 97/78 upon co-administration in rats: An in-vivo &in-vitro analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26321516/),[h·μg] / [ml],5.44,148342,DB00615,Rifabutin
,26321516,AUC0-last,"The AUC0-last values were (4.03 ± 0.60) and (5.44 ± 1.15) μg h mL(-1) upon 97/78 administration alone, while the values were decreased to (1.13 ± 0.10) and (1.23 ± 1.13) μg h mL(-1) upon rifabutin co-administration in male and female rats respectively.",Rifabutin reduces systemic exposure of an antimalarial drug 97/78 upon co-administration in rats: An in-vivo &in-vitro analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26321516/),[h·μg] / [ml],1.13,148343,DB00615,Rifabutin
,26321516,AUC0-last,"The AUC0-last values were (4.03 ± 0.60) and (5.44 ± 1.15) μg h mL(-1) upon 97/78 administration alone, while the values were decreased to (1.13 ± 0.10) and (1.23 ± 1.13) μg h mL(-1) upon rifabutin co-administration in male and female rats respectively.",Rifabutin reduces systemic exposure of an antimalarial drug 97/78 upon co-administration in rats: An in-vivo &in-vitro analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26321516/),[h·μg] / [ml],1.23,148344,DB00615,Rifabutin
,26321516,plasma protein binding,The extent of plasma protein binding of 97/63 was found to be decreased from 54%-55% to 6%-8% upon rifabutin addition.,Rifabutin reduces systemic exposure of an antimalarial drug 97/78 upon co-administration in rats: An in-vivo &in-vitro analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26321516/),,6,148345,DB00615,Rifabutin
,33294914,AUC0-24,"Among 15 children with median (IQR) age 13.1 (10.9-14.0) years and weight 25.5 (22.3-30.5) kg, the median (IQR) rifabutin AUC0-24 was 5.21 (4.38-6.60) μg·h/mL.",Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33294914/),[h·μg] / [ml],5.21,153100,DB00615,Rifabutin
below,33294914,AUC0-24,Four participants had AUC0-24 below 3.8 μg·h/mL (a target for the population average exposure) at week 2 and all had AUC0-24 higher than 3.8 μg·h/mL at the 4 and 8 week visits.,Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33294914/),[h·μg] / [ml],3.8,153101,DB00615,Rifabutin
higher,33294914,AUC0-24,Four participants had AUC0-24 below 3.8 μg·h/mL (a target for the population average exposure) at week 2 and all had AUC0-24 higher than 3.8 μg·h/mL at the 4 and 8 week visits.,Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33294914/),[h·μg] / [ml],3.8,153102,DB00615,Rifabutin
<,25406657,AUC0-24,"86% of patients on the tiw rifabutin arm had an AUC0-24 < 4.5 μg.h/mL, which has previously been associated with acquired rifamycin resistance (ARR).",Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406657/),[h·μg] / [ml],4.5,155340,DB00615,Rifabutin
,10589373,oral bioavailability,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),%,52 to 55,162570,DB00615,Rifabutin
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],1.01 to 1.52,162571,DB00615,Rifabutin
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],2.41 to 2.85,162572,DB00615,Rifabutin
,10589373,elimination half-life,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),h,3.3 to 4.9,162573,DB00615,Rifabutin
,10589373,total body clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],29.2 to 58.1,162574,DB00615,Rifabutin
,10589373,renal clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],6.7 to 12.8,162575,DB00615,Rifabutin
,29061739,AUC0-336,"Steady-state rifampin reduced bedaquiline AUC0-336 approximately 45%, from 47.69 h·μg/ml in period 1 to 26.33 h·μg/ml in period 2.","Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29061739/),[h·μg] / [ml],47.69,175789,DB00615,Rifabutin
,29061739,AUC0-336,"Steady-state rifampin reduced bedaquiline AUC0-336 approximately 45%, from 47.69 h·μg/ml in period 1 to 26.33 h·μg/ml in period 2.","Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29061739/),[h·μg] / [ml],26.33,175790,DB00615,Rifabutin
,29061739,apparent clearance,Bedaquiline apparent clearance accelerated 24% in rifampin-treated subjects from 6.59 liters/h in period 1 to 8.19 liters/h in period 2.,"Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29061739/),[l] / [h],6.59,175791,DB00615,Rifabutin
,29061739,apparent clearance,Bedaquiline apparent clearance accelerated 24% in rifampin-treated subjects from 6.59 liters/h in period 1 to 8.19 liters/h in period 2.,"Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29061739/),[l] / [h],8.19,175792,DB00615,Rifabutin
,8726008,time at which the plasma concentration was maximal (Tmax),"Kinetics on days 13 and 16 demonstrated that RBT (300 or 450 mg) was readily absorbed, with the time at which the plasma concentration was maximal (Tmax) ranging between 2.6 and 2.9 h.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),h,2.6 and 2.9,189944,DB00615,Rifabutin
,8726008,steady-state maximal plasma concentrations (Cmax),"At these two doses, the mean steady-state maximal plasma concentrations (Cmax) were 250 and 430 ng/ml on day 13 and 245 and 458 ng/ml on day 16, respectively.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),[ng] / [ml],250,189945,DB00615,Rifabutin
,8726008,steady-state maximal plasma concentrations (Cmax),"At these two doses, the mean steady-state maximal plasma concentrations (Cmax) were 250 and 430 ng/ml on day 13 and 245 and 458 ng/ml on day 16, respectively.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),[ng] / [ml],430,189946,DB00615,Rifabutin
,8726008,steady-state maximal plasma concentrations (Cmax),"At these two doses, the mean steady-state maximal plasma concentrations (Cmax) were 250 and 430 ng/ml on day 13 and 245 and 458 ng/ml on day 16, respectively.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),[ng] / [ml],245,189947,DB00615,Rifabutin
,8726008,steady-state maximal plasma concentrations (Cmax),"At these two doses, the mean steady-state maximal plasma concentrations (Cmax) were 250 and 430 ng/ml on day 13 and 245 and 458 ng/ml on day 16, respectively.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),[ng] / [ml],458,189948,DB00615,Rifabutin
,8726008,oral clearance (CLs/F),"No significant differences were apparent in the mean oral clearance (CLs/F) estimates (range, 1.60 to 1.77 liters/h/kg), which were dose independent and similar for the 2 assessment days, as was the urinary recovery of RBT and its 25-deacetyl metabolite.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),[l] / [h·kg],1.60 to 1.77,189949,DB00615,Rifabutin
,8726008,AUC metabolite/parent ratio,Low urinary recovery of 25-deacetyl RBT and an AUC metabolite/parent ratio of 0.1 suggest that there is minimal metabolism of RBT via the deacetylation pathway.,Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),,0.1,189950,DB00615,Rifabutin
,17542762,area under the concentration-time curve from 0-21 hours (AUC(0-21)),"When rifabutin was coadministered with nelfinavir, its area under the concentration-time curve from 0-21 hours (AUC(0-21)) increased 22% (geometric mean 5.01 microg.hr/ml [90% confidence interval (CI) 3.25-7.71] with nelfinavir vs 4.10 microg.hr/ml [90% CI 3.18-5.27] without nelfinavir; geometric mean ratio 1.22 [90% CI 0.78-1.92]).",Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542762/),[h·μg] / [ml],5.01,191030,DB00615,Rifabutin
,17542762,area under the concentration-time curve from 0-21 hours (AUC(0-21)),"When rifabutin was coadministered with nelfinavir, its area under the concentration-time curve from 0-21 hours (AUC(0-21)) increased 22% (geometric mean 5.01 microg.hr/ml [90% confidence interval (CI) 3.25-7.71] with nelfinavir vs 4.10 microg.hr/ml [90% CI 3.18-5.27] without nelfinavir; geometric mean ratio 1.22 [90% CI 0.78-1.92]).",Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542762/),[h·μg] / [ml],4.10,191031,DB00615,Rifabutin
,15961763,peak plasma concentrations,"The dose versus area under the curve-relationship for 17-AAG was linear (r(2) = .71) over the dose range 10 to 450 mg/m(2)/week, with peak plasma concentrations of 8,998 mug/L (standard deviation, 2,881) at the highest dose level.","Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15961763/),[μg] / [l],"8,998",191684,DB00615,Rifabutin
,9687400,absorption rate constant,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),1/[h],0. 201,198972,DB00615,Rifabutin
,9687400,clearance/bioavailability (CL/F,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),[l] / [h],60.9,198973,DB00615,Rifabutin
,9687400,volume of the central compartment/bioavailability,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),l,231,198974,DB00615,Rifabutin
,9687400,intercompartmental clearance,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),[l] / [h],60.3,198975,DB00615,Rifabutin
,9687400,volume of the peripheral compartment/bioavailability (Vp/F,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),l,"1,050",198976,DB00615,Rifabutin
,9687400,distribution,"The distribution and elimination half-lives were 1.24 and 25.4 h, respectively.",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),h,1.24,198977,DB00615,Rifabutin
,9687400,elimination half-lives,"The distribution and elimination half-lives were 1.24 and 25.4 h, respectively.",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),h,25.4,198978,DB00615,Rifabutin
,25281400,AUC0-48,"The median (range) AUC0-48 of rifabutin was 6.91 (3.52-8.67) μg · h/mL, the median (range) Cmax of rifabutin was 0.39 (0.19-0.46) μg/mL, the median (range) AUC0-48 of 25-O-desacetyl rifabutin was 5.73 (2.85-9.13) μg · h/mL and the median (range) Cmax of 25-O-desacetyl rifabutin was 0.17 (0.08-0.32) μg/mL.",Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25281400/),[h·μg] / [ml],6.91,204209,DB00615,Rifabutin
,25281400,Cmax,"The median (range) AUC0-48 of rifabutin was 6.91 (3.52-8.67) μg · h/mL, the median (range) Cmax of rifabutin was 0.39 (0.19-0.46) μg/mL, the median (range) AUC0-48 of 25-O-desacetyl rifabutin was 5.73 (2.85-9.13) μg · h/mL and the median (range) Cmax of 25-O-desacetyl rifabutin was 0.17 (0.08-0.32) μg/mL.",Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25281400/),[μg] / [ml],0.39,204210,DB00615,Rifabutin
,25281400,AUC0-48,"The median (range) AUC0-48 of rifabutin was 6.91 (3.52-8.67) μg · h/mL, the median (range) Cmax of rifabutin was 0.39 (0.19-0.46) μg/mL, the median (range) AUC0-48 of 25-O-desacetyl rifabutin was 5.73 (2.85-9.13) μg · h/mL and the median (range) Cmax of 25-O-desacetyl rifabutin was 0.17 (0.08-0.32) μg/mL.",Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25281400/),[h·μg] / [ml],5.73,204211,DB00615,Rifabutin
,25281400,Cmax,"The median (range) AUC0-48 of rifabutin was 6.91 (3.52-8.67) μg · h/mL, the median (range) Cmax of rifabutin was 0.39 (0.19-0.46) μg/mL, the median (range) AUC0-48 of 25-O-desacetyl rifabutin was 5.73 (2.85-9.13) μg · h/mL and the median (range) Cmax of 25-O-desacetyl rifabutin was 0.17 (0.08-0.32) μg/mL.",Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25281400/),[μg] / [ml],0.17,204212,DB00615,Rifabutin
,11808861,clearance (CL),"Systemic antipyrine clearance (CL) increased from 31.8 ml/min/kg (controls) by 64% and 42% following repeated exposure to RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[ml] / [kg·min],31.8,207919,DB00615,Rifabutin
,11808861,F,"Estimate of F for antipyrine decreased from 0.97 in controls to 0.58 and 0.82 in animals treated with RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),,0.97,207920,DB00615,Rifabutin
,11808861,F,"Estimate of F for antipyrine decreased from 0.97 in controls to 0.58 and 0.82 in animals treated with RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),,0.58,207921,DB00615,Rifabutin
,11808861,F,"Estimate of F for antipyrine decreased from 0.97 in controls to 0.58 and 0.82 in animals treated with RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),,0.82,207922,DB00615,Rifabutin
,11808861,P450,"The content of P450 (nmol/mg protein) in the liver increased from 0.61 (control) to 1.36 following RFM and 0.82 for RBT, while no significant changes were observed for the GI tract.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[nM] / [mg],0.61,207923,DB00615,Rifabutin
,11808861,P450,"The content of P450 (nmol/mg protein) in the liver increased from 0.61 (control) to 1.36 following RFM and 0.82 for RBT, while no significant changes were observed for the GI tract.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[nM] / [mg],1.36,207924,DB00615,Rifabutin
,11808861,P450,"The content of P450 (nmol/mg protein) in the liver increased from 0.61 (control) to 1.36 following RFM and 0.82 for RBT, while no significant changes were observed for the GI tract.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[nM] / [mg],0.82,207925,DB00615,Rifabutin
,8597321,area under the plasma concentration curve,Mean increases in the area under the plasma concentration curve compared with the time curve over a 24-hour dosing interval were 82% (5442 +/- 2404 ng.h/mL compared with 3025 +/- 1117 ng.h/mL; P less than or equal to 0.05) for rifabutin and 216% (959 +/- 529 ng.h/mL compared with 244 +/- 141 ng.h/mL; P less than or equal to 0.05) for LM565.,Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8597321/),[h·ng] / [ml],5442,209039,DB00615,Rifabutin
,8597321,area under the plasma concentration curve,Mean increases in the area under the plasma concentration curve compared with the time curve over a 24-hour dosing interval were 82% (5442 +/- 2404 ng.h/mL compared with 3025 +/- 1117 ng.h/mL; P less than or equal to 0.05) for rifabutin and 216% (959 +/- 529 ng.h/mL compared with 244 +/- 141 ng.h/mL; P less than or equal to 0.05) for LM565.,Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8597321/),[h·ng] / [ml],3025,209040,DB00615,Rifabutin
,8597321,area under the plasma concentration curve,Mean increases in the area under the plasma concentration curve compared with the time curve over a 24-hour dosing interval were 82% (5442 +/- 2404 ng.h/mL compared with 3025 +/- 1117 ng.h/mL; P less than or equal to 0.05) for rifabutin and 216% (959 +/- 529 ng.h/mL compared with 244 +/- 141 ng.h/mL; P less than or equal to 0.05) for LM565.,Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8597321/),[h·ng] / [ml],959,209041,DB00615,Rifabutin
,8597321,area under the plasma concentration curve,Mean increases in the area under the plasma concentration curve compared with the time curve over a 24-hour dosing interval were 82% (5442 +/- 2404 ng.h/mL compared with 3025 +/- 1117 ng.h/mL; P less than or equal to 0.05) for rifabutin and 216% (959 +/- 529 ng.h/mL compared with 244 +/- 141 ng.h/mL; P less than or equal to 0.05) for LM565.,Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8597321/),[h·ng] / [ml],244,209042,DB00615,Rifabutin
,33229425,maximum concentrations (C max),"Median maximum concentrations (C max) in the rifampin and rifabutin arms were 2.14 and 3.35 mg/liter, while median AUC0-24 values were 30.1 and 59.5 mg·h/liter, respectively.",Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33229425/),[mg] / [l],2.14,210110,DB00615,Rifabutin
,33229425,maximum concentrations (C max),"Median maximum concentrations (C max) in the rifampin and rifabutin arms were 2.14 and 3.35 mg/liter, while median AUC0-24 values were 30.1 and 59.5 mg·h/liter, respectively.",Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33229425/),[mg] / [l],3.35,210111,DB00615,Rifabutin
,33229425,AUC0-24,"Median maximum concentrations (C max) in the rifampin and rifabutin arms were 2.14 and 3.35 mg/liter, while median AUC0-24 values were 30.1 and 59.5 mg·h/liter, respectively.",Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33229425/),[h·mg] / [l],30.1,210112,DB00615,Rifabutin
,33229425,AUC0-24,"Median maximum concentrations (C max) in the rifampin and rifabutin arms were 2.14 and 3.35 mg/liter, while median AUC0-24 values were 30.1 and 59.5 mg·h/liter, respectively.",Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33229425/),[h·mg] / [l],59.5,210113,DB00615,Rifabutin
,29723418,apparent clearance,Doravirine apparent clearance increased from 5.9 L/h without rifabutin to 12.2 L/h when coadministered.,Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29723418/),[l] / [h],5.9,211704,DB00615,Rifabutin
,29723418,apparent clearance,Doravirine apparent clearance increased from 5.9 L/h without rifabutin to 12.2 L/h when coadministered.,Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29723418/),[l] / [h],12.2,211705,DB00615,Rifabutin
,10594472,Cmax,Cmax was 0.34+/-0.,Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594472/),,0.34,213529,DB00615,Rifabutin
,10594472,tmax,"tmax was 4.2+/-1.5 and 3.3+/-2.3 h (P=0.17) in NWS and WS patients, respectively.",Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594472/),h,4.2,213530,DB00615,Rifabutin
,10594472,tmax,"tmax was 4.2+/-1.5 and 3.3+/-2.3 h (P=0.17) in NWS and WS patients, respectively.",Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594472/),h,3.3,213531,DB00615,Rifabutin
,10594472,V/F,V/F was 2905+/-1646 l in NWS patients and 1701+/-492 l (P=0.07) for the WS group.,Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594472/),l,2905,213532,DB00615,Rifabutin
,10594472,V/F,V/F was 2905+/-1646 l in NWS patients and 1701+/-492 l (P=0.07) for the WS group.,Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594472/),l,1701,213533,DB00615,Rifabutin
,10594472,V/F,These differences are less pronounced following normalization of V/F to patients body weight (43.7+/-20.1 vs 35.4+/-10.3 l kg-1 ).,Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594472/),[l] / [kg],43.7,213534,DB00615,Rifabutin
,10594472,V/F,These differences are less pronounced following normalization of V/F to patients body weight (43.7+/-20.1 vs 35.4+/-10.3 l kg-1 ).,Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594472/),[l] / [kg],35.4,213535,DB00615,Rifabutin
,10594472,"t1/2,lambdaz","t1/2,lambdaz tended to be shorter in patients with WS (31.4+/-12.9 vs 46.0+/-23.5 h, P=0.12).",Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594472/),h,31.4,213536,DB00615,Rifabutin
,10594472,"t1/2,lambdaz","t1/2,lambdaz tended to be shorter in patients with WS (31.4+/-12.9 vs 46.0+/-23.5 h, P=0.12).",Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594472/),h,46.0,213537,DB00615,Rifabutin
,1330396,maximum concentration,"The mean +/- SD maximum concentration for rifabutin in plasma was 238 +/- 65, 156 +/- 52, and 188 +/- 50 ng/ml, time to reach peak concentration was 2.5 +/- 0.4, 5.4 +/- 1.6, and 3.0 +/- 1.1 hours, and the area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)] was 2989 +/- 726, 2640 +/- 891, and 2516 +/- 601 ng.hr/ml for the solution and the capsule during the fed and fasted states, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),[ng] / [ml],238,216500,DB00615,Rifabutin
,1330396,maximum concentration,"The mean +/- SD maximum concentration for rifabutin in plasma was 238 +/- 65, 156 +/- 52, and 188 +/- 50 ng/ml, time to reach peak concentration was 2.5 +/- 0.4, 5.4 +/- 1.6, and 3.0 +/- 1.1 hours, and the area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)] was 2989 +/- 726, 2640 +/- 891, and 2516 +/- 601 ng.hr/ml for the solution and the capsule during the fed and fasted states, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),[ng] / [ml],156,216501,DB00615,Rifabutin
,1330396,maximum concentration,"The mean +/- SD maximum concentration for rifabutin in plasma was 238 +/- 65, 156 +/- 52, and 188 +/- 50 ng/ml, time to reach peak concentration was 2.5 +/- 0.4, 5.4 +/- 1.6, and 3.0 +/- 1.1 hours, and the area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)] was 2989 +/- 726, 2640 +/- 891, and 2516 +/- 601 ng.hr/ml for the solution and the capsule during the fed and fasted states, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),[ng] / [ml],188,216502,DB00615,Rifabutin
,1330396,time to reach peak concentration,"The mean +/- SD maximum concentration for rifabutin in plasma was 238 +/- 65, 156 +/- 52, and 188 +/- 50 ng/ml, time to reach peak concentration was 2.5 +/- 0.4, 5.4 +/- 1.6, and 3.0 +/- 1.1 hours, and the area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)] was 2989 +/- 726, 2640 +/- 891, and 2516 +/- 601 ng.hr/ml for the solution and the capsule during the fed and fasted states, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),h,2.5,216503,DB00615,Rifabutin
,1330396,time to reach peak concentration,"The mean +/- SD maximum concentration for rifabutin in plasma was 238 +/- 65, 156 +/- 52, and 188 +/- 50 ng/ml, time to reach peak concentration was 2.5 +/- 0.4, 5.4 +/- 1.6, and 3.0 +/- 1.1 hours, and the area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)] was 2989 +/- 726, 2640 +/- 891, and 2516 +/- 601 ng.hr/ml for the solution and the capsule during the fed and fasted states, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),h,5.4,216504,DB00615,Rifabutin
,1330396,time to reach peak concentration,"The mean +/- SD maximum concentration for rifabutin in plasma was 238 +/- 65, 156 +/- 52, and 188 +/- 50 ng/ml, time to reach peak concentration was 2.5 +/- 0.4, 5.4 +/- 1.6, and 3.0 +/- 1.1 hours, and the area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)] was 2989 +/- 726, 2640 +/- 891, and 2516 +/- 601 ng.hr/ml for the solution and the capsule during the fed and fasted states, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),h,3.0,216505,DB00615,Rifabutin
,1330396,area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)],"The mean +/- SD maximum concentration for rifabutin in plasma was 238 +/- 65, 156 +/- 52, and 188 +/- 50 ng/ml, time to reach peak concentration was 2.5 +/- 0.4, 5.4 +/- 1.6, and 3.0 +/- 1.1 hours, and the area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)] was 2989 +/- 726, 2640 +/- 891, and 2516 +/- 601 ng.hr/ml for the solution and the capsule during the fed and fasted states, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),[h·ng] / [ml],2989,216506,DB00615,Rifabutin
,1330396,area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)],"The mean +/- SD maximum concentration for rifabutin in plasma was 238 +/- 65, 156 +/- 52, and 188 +/- 50 ng/ml, time to reach peak concentration was 2.5 +/- 0.4, 5.4 +/- 1.6, and 3.0 +/- 1.1 hours, and the area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)] was 2989 +/- 726, 2640 +/- 891, and 2516 +/- 601 ng.hr/ml for the solution and the capsule during the fed and fasted states, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),[h·ng] / [ml],2640,216507,DB00615,Rifabutin
,1330396,area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)],"The mean +/- SD maximum concentration for rifabutin in plasma was 238 +/- 65, 156 +/- 52, and 188 +/- 50 ng/ml, time to reach peak concentration was 2.5 +/- 0.4, 5.4 +/- 1.6, and 3.0 +/- 1.1 hours, and the area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)] was 2989 +/- 726, 2640 +/- 891, and 2516 +/- 601 ng.hr/ml for the solution and the capsule during the fed and fasted states, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),[h·ng] / [ml],2516,216508,DB00615,Rifabutin
,1330396,Percentage of dose excreted in,"Percentage of dose excreted in the urine as unchanged rifabutin was 11.0% +/- 2.4%, 11.4% +/- 4.9%, and 9.1% +/- 2.1% for treatments A, B, and C, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),%,11.0,216509,DB00615,Rifabutin
,1330396,Percentage of dose excreted in,"Percentage of dose excreted in the urine as unchanged rifabutin was 11.0% +/- 2.4%, 11.4% +/- 4.9%, and 9.1% +/- 2.1% for treatments A, B, and C, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),%,11.4,216510,DB00615,Rifabutin
,1330396,Percentage of dose excreted in,"Percentage of dose excreted in the urine as unchanged rifabutin was 11.0% +/- 2.4%, 11.4% +/- 4.9%, and 9.1% +/- 2.1% for treatments A, B, and C, respectively.",Rifabutin absorption in humans: relative bioavailability and food effect. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),%,9.1,216511,DB00615,Rifabutin
,1330396,AUC(0-infinity),"The corresponding AUC(0-infinity) values for the equiactive metabolite 25-O-deacetyl-rifabutin, were 400 +/- 184, 361 +/- 187, and 298 +/- 102 ng.hr/ml.(ABSTRACT TRUNCATED AT 250 WORDS)",Rifabutin absorption in humans: relative bioavailability and food effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),[h·ng] / [ml],400,216512,DB00615,Rifabutin
,1330396,AUC(0-infinity),"The corresponding AUC(0-infinity) values for the equiactive metabolite 25-O-deacetyl-rifabutin, were 400 +/- 184, 361 +/- 187, and 298 +/- 102 ng.hr/ml.(ABSTRACT TRUNCATED AT 250 WORDS)",Rifabutin absorption in humans: relative bioavailability and food effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),[h·ng] / [ml],361,216513,DB00615,Rifabutin
,1330396,AUC(0-infinity),"The corresponding AUC(0-infinity) values for the equiactive metabolite 25-O-deacetyl-rifabutin, were 400 +/- 184, 361 +/- 187, and 298 +/- 102 ng.hr/ml.(ABSTRACT TRUNCATED AT 250 WORDS)",Rifabutin absorption in humans: relative bioavailability and food effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330396/),[h·ng] / [ml],298,216514,DB00615,Rifabutin
,11503009,Oral clearance,Oral clearance of rifabutin was similar in both groups (321 mL/min in group 2 versus 372 mL/min in group 1; P = .34).,A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11503009/),[ml] / [min],321,232595,DB00615,Rifabutin
,11503009,Oral clearance,Oral clearance of rifabutin was similar in both groups (321 mL/min in group 2 versus 372 mL/min in group 1; P = .34).,A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11503009/),[ml] / [min],372,232596,DB00615,Rifabutin
,11503009,C(max),Rifabutin C(max) values were significantly lower in group 2 (310 ng/mL versus 496 ng/mL in group 1; P = .004).,A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11503009/),[ng] / [ml],310,232597,DB00615,Rifabutin
,11503009,C(max),Rifabutin C(max) values were significantly lower in group 2 (310 ng/mL versus 496 ng/mL in group 1; P = .004).,A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11503009/),[ng] / [ml],496,232598,DB00615,Rifabutin
,30500116,maximum M2 concentrations (Cmax ),"In the rifabutin group maximum M2 concentrations (Cmax ) increased significantly (P < .001) from 47.59 to 79.53 ng/mL, and clearance slowed slightly (P = .01).",Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500116/),[ng] / [ml],47.59,233337,DB00615,Rifabutin
,30500116,maximum M2 concentrations (Cmax ),"In the rifabutin group maximum M2 concentrations (Cmax ) increased significantly (P < .001) from 47.59 to 79.53 ng/mL, and clearance slowed slightly (P = .01).",Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500116/),[ng] / [ml],79.53,233338,DB00615,Rifabutin
,30500116,Cmax,"In rifampin recipients M2 Cmax doubled (48.44 to 101.52 ng/mL), but M2 clearance and time to Cmax significantly (P < .001) increased, and AUC0-∞ and mean residence time significantly decreased (P < .001).",Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500116/),[ng] / [ml],48.44 to 101.52,233339,DB00615,Rifabutin
,9812178,t1/2 beta,The clinically relevant t1/2 beta is about 3 to 5 hours.,Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812178/),h,3 to 5,239662,DB00615,Rifabutin
,9812178,apparent oral clearance,"The pharmacokinetics of ritonavir are relatively linear after multiple doses, with apparent oral clearance averaging 7 to 9 L/h.",Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812178/),[l] / [h],7 to 9,239663,DB00615,Rifabutin
,11760222,plasma clearance (CL),"Results showed that repeated exposure of rifabutin, relative to control, caused a 16% increase in the plasma clearance (CL) of ciprofloxacin after i.v. dosing (4.19 vs. 4.87 L/h/kg).",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[l] / [h·kg],4.19,256851,DB00615,Rifabutin
,11760222,plasma clearance (CL),"Results showed that repeated exposure of rifabutin, relative to control, caused a 16% increase in the plasma clearance (CL) of ciprofloxacin after i.v. dosing (4.19 vs. 4.87 L/h/kg).",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[l] / [h·kg],4.87,256852,DB00615,Rifabutin
,11760222,elimination half-life (T1/2),Estimates of elimination half-life (T1/2) were not affected by rifabutin (control: 0.81 vs. rifabutin pretreated: 1.18 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,0.81,256853,DB00615,Rifabutin
,11760222,elimination half-life (T1/2),Estimates of elimination half-life (T1/2) were not affected by rifabutin (control: 0.81 vs. rifabutin pretreated: 1.18 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,1.18,256854,DB00615,Rifabutin
,11760222,maximal plasma concentration (Cmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[μg] / [ml],1.34,256855,DB00615,Rifabutin
,11760222,maximal plasma concentration (Cmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[μg] / [ml],0.91,256856,DB00615,Rifabutin
,11760222,time to Cmax (Tmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,0.17,256857,DB00615,Rifabutin
,11760222,time to Cmax (Tmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,0.33,256858,DB00615,Rifabutin
,11760222,T1/2,"With or without rifabutin pretreatment, the T1/2 estimates of ciprofloxacin for p.o. dosing were similar (2.37-2.58 h) and were approximately twice as long as those obtained after i.v. dosing.",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,2.37-2.58,256859,DB00615,Rifabutin
,11760222,oral bioavailability (F),"Since the changes in systemic exposure as a result of rifabutin pretreatment were similar after i.v. and p.o. dosing, the oral bioavailability (F) of ciprofloxacin remained unaffected by rifabutin at approximately 38%.",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),%,38,256860,DB00615,Rifabutin
<,24200269,Peak RBT concentration,"Peak RBT concentration was below the lower therapeutic limit (<0.3 μg/ml) in seven patients, while 10 patients had trough concentrations below the minimal inhibitory concentration against Mycobacterium tuberculosis (0.06 μg/ml), suggesting that the RBT dosage may be inadequate.",Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24200269/),[μg] / [ml],0.3,272406,DB00615,Rifabutin
,24200269,minimal inhibitory concentration,"Peak RBT concentration was below the lower therapeutic limit (<0.3 μg/ml) in seven patients, while 10 patients had trough concentrations below the minimal inhibitory concentration against Mycobacterium tuberculosis (0.06 μg/ml), suggesting that the RBT dosage may be inadequate.",Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24200269/),[μg] / [ml],0.06,272407,DB00615,Rifabutin
,11345645,"""peak"" plasma 17AAG concentrations","Sequential reduction of the 17AAG dose to 40 and 26.67 mg/kg resulted in ""peak"" plasma 17AAG concentrations between 8.9 and 19.0 micrograms/ml, and 4.8 and 6.1 micrograms/ml, respectively.",Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345645/),[μg] / [ml],8.9 and 19.0,274006,DB00615,Rifabutin
,11345645,"""peak"" plasma 17AAG concentrations","Sequential reduction of the 17AAG dose to 40 and 26.67 mg/kg resulted in ""peak"" plasma 17AAG concentrations between 8.9 and 19.0 micrograms/ml, and 4.8 and 6.1 micrograms/ml, respectively.",Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345645/),[μg] / [ml],4.8,274007,DB00615,Rifabutin
,11345645,"""peak"" plasma 17AAG concentrations","Sequential reduction of the 17AAG dose to 40 and 26.67 mg/kg resulted in ""peak"" plasma 17AAG concentrations between 8.9 and 19.0 micrograms/ml, and 4.8 and 6.1 micrograms/ml, respectively.",Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345645/),[μg] / [ml],6.1,274008,DB00615,Rifabutin
,11345645,AUC,"Noncompartmental analysis of the plasma 17AAG concentration versus time data showed an increase in AUC from 402 to 625 and 1738 micrograms/ml.min when the 17AAG dose increased from 26.67 to 40 and 60 mg/kg, respectively.",Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345645/),[μg] / [min·ml],402,274009,DB00615,Rifabutin
,11345645,AUC,"Noncompartmental analysis of the plasma 17AAG concentration versus time data showed an increase in AUC from 402 to 625 and 1738 micrograms/ml.min when the 17AAG dose increased from 26.67 to 40 and 60 mg/kg, respectively.",Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345645/),[μg] / [min·ml],625,274010,DB00615,Rifabutin
,11345645,AUC,"Noncompartmental analysis of the plasma 17AAG concentration versus time data showed an increase in AUC from 402 to 625 and 1738 micrograms/ml.min when the 17AAG dose increased from 26.67 to 40 and 60 mg/kg, respectively.",Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345645/),[μg] / [min·ml],1738,274011,DB00615,Rifabutin
,11345645,total body clearance,"Across the range of doses studied, 17AAG total body clearance varied from 34 to 66 ml/min per kg.",Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345645/),[ml] / [kg·min],34 to 66,274012,DB00615,Rifabutin
,11345645,peak plasma,"A repeat i.v. study using a 40 mg/kg dose of this new formulation produced peak plasma 17AAG concentrations of 20.2-38.4 micrograms/ml, and a 17AAG AUC of 912 micrograms/ml.min, which was approximately 50% greater than the AUC produced by a 40 mg/kg dose of microdispersed 17AAG.",Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345645/),[μg] / [ml],20.2-38.4,274013,DB00615,Rifabutin
,11345645,AUC,"A repeat i.v. study using a 40 mg/kg dose of this new formulation produced peak plasma 17AAG concentrations of 20.2-38.4 micrograms/ml, and a 17AAG AUC of 912 micrograms/ml.min, which was approximately 50% greater than the AUC produced by a 40 mg/kg dose of microdispersed 17AAG.",Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345645/),[μg] / [min·ml],912,274014,DB00615,Rifabutin
,11345645,bioavailabilities,"The bioavailabilities of 17AAG after i.p. and oral delivery were 99% and 24%, respectively.",Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345645/),%,99,274015,DB00615,Rifabutin
,11345645,bioavailabilities,"The bioavailabilities of 17AAG after i.p. and oral delivery were 99% and 24%, respectively.",Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345645/),%,24,274016,DB00615,Rifabutin
,32590942,Cmax,"The Cmax and AUC0-12h medians in arm A (Cmax = 296 ng/mL, IQR: 205-45; AUC0-12h = 2528 ng.h/mL, IQR: 1684-2735) were lower than those in arm B (Cmax = 600 ng/mL, IQR: 403-717; AUC0-12h = 4042.5 ng.h/mL, IQR: 3469-5761), with a statistically significant difference in AUC0-12h (p = 0.044) but not in Cmax (p = 0.313).",Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32590942/),[ng] / [ml],296,274131,DB00615,Rifabutin
,32590942,AUC0-12h,"The Cmax and AUC0-12h medians in arm A (Cmax = 296 ng/mL, IQR: 205-45; AUC0-12h = 2528 ng.h/mL, IQR: 1684-2735) were lower than those in arm B (Cmax = 600 ng/mL, IQR: 403-717; AUC0-12h = 4042.5 ng.h/mL, IQR: 3469-5761), with a statistically significant difference in AUC0-12h (p = 0.044) but not in Cmax (p = 0.313).",Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32590942/),[h·ng] / [ml],2528,274132,DB00615,Rifabutin
,32590942,Cmax,"The Cmax and AUC0-12h medians in arm A (Cmax = 296 ng/mL, IQR: 205-45; AUC0-12h = 2528 ng.h/mL, IQR: 1684-2735) were lower than those in arm B (Cmax = 600 ng/mL, IQR: 403-717; AUC0-12h = 4042.5 ng.h/mL, IQR: 3469-5761), with a statistically significant difference in AUC0-12h (p = 0.044) but not in Cmax (p = 0.313).",Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32590942/),[ng] / [ml],600,274133,DB00615,Rifabutin
,32590942,AUC0-12h,"The Cmax and AUC0-12h medians in arm A (Cmax = 296 ng/mL, IQR: 205-45; AUC0-12h = 2528 ng.h/mL, IQR: 1684-2735) were lower than those in arm B (Cmax = 600 ng/mL, IQR: 403-717; AUC0-12h = 4042.5 ng.h/mL, IQR: 3469-5761), with a statistically significant difference in AUC0-12h (p = 0.044) but not in Cmax (p = 0.313).",Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32590942/),[h·ng] / [ml],4042.5,274134,DB00615,Rifabutin
,32590942,Tmax,No significant differences were observed in Tmax (3 h versus 4 h).,Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32590942/),h,3,274135,DB00615,Rifabutin
,32590942,Tmax,No significant differences were observed in Tmax (3 h versus 4 h).,Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32590942/),h,4,274136,DB00615,Rifabutin
<,32590942,Cmax,"Five patients had a Cmax below the plasma therapeutic limit (< 300 ng/mL) in the 150 mg RBT arm, while the Cmax was above this threshold for all patients in the 300 mg RBT arm.",Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32590942/),[ng] / [ml],300,274137,DB00615,Rifabutin
>,32590942,minimum inhibitory concentration (MIC),"Additionally, at 48 h after drug ingestion, all patients had a mycobacterial minimum inhibitory concentration (MIC) above the limit (> 64 ng/mL) in the 300 mg RBT arm, while 4/9 patients had such values in the 150 mg RBT arm.",Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32590942/),[ng] / [ml],64,274138,DB00615,Rifabutin
